Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-05-24
DOI
10.1038/srep26345
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients
- (2015) Amir Khammari et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prognostic and predictive immune gene signatures in breast cancer
- (2015) Davide Bedognetti et al. CURRENT OPINION IN ONCOLOGY
- The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
- (2015) Thomas F. Gajewski SEMINARS IN ONCOLOGY
- Combination Immunotherapy for Melanoma
- (2015) Howard L. Kaufman JAMA Oncology
- Direct T cell–tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme
- (2014) P Jin et al. BRITISH JOURNAL OF CANCER
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- TG1042 (Adenovirus-interferon-γ) in Primary Cutaneous B-cell Lymphomas: A Phase II Clinical Trial
- (2014) Brigitte Dreno et al. PLoS One
- CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2
- (2013) D Bedognetti et al. BRITISH JOURNAL OF CANCER
- The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
- (2013) Jérôme Galon et al. IMMUNITY
- Prediction of Response to Anticancer Immunotherapy Using Gene Signatures
- (2013) Ena Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
- (2013) Fernando Ulloa-Montoya et al. JOURNAL OF CLINICAL ONCOLOGY
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Mechanisms of mesenchymal stromal cell immunomodulation
- (2012) Karen English IMMUNOLOGY AND CELL BIOLOGY
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma
- (2011) G. R. Weiss et al. CLINICAL CANCER RESEARCH
- Global transcriptome analysis of human bone marrow stromal cells (BMSC) reveals proliferative, mobile and interactive cells that produce abundant extracellular matrix proteins, some of which may affect BMSC potency
- (2011) Jiaqiang Ren et al. CYTOTHERAPY
- Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes
- (2011) Rafael Carretero et al. INTERNATIONAL JOURNAL OF CANCER
- Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis
- (2011) Tara L Spivey et al. Journal of Translational Medicine
- Gene-expression profiling in vaccine therapy and immunotherapy for cancer
- (2010) Davide Bedognetti et al. Expert Review of Vaccines
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
- (2009) H. Harlin et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started